Developers
21 Results
Advanced Search
Showing
Narrow Your Results Use the filters below to refine your search
By Application
By Brand
By Industry
-
-
Press Release: Merck Enters Into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting (SMC™) Technolog
Merck and Singulex, the developer and leading provider of Single Molecule Counting (SMCTM) technology for clinical diagnostics and scientific discovery, today announced that they have entered into a definitive agreement under which Merck will control and manage the Singulex Life Science Research business. -
Antibodies | Life Science Research | Merck
Antibodies have become critical tools for most areas of life science research, primarily for their use as molecular tags for specific labeling and detection. Merck is a leading antibody developer providing high quality reagents validated for use in immunostaining, blotting, purification, ChIP, flow cytometry and multiplexed assays. Learn about the key features of antibodies and immunochemical techniques used biological research. -
BioReliance® Cell and Gene Therapy Testing Services | Merck
Our BioReliance® gene therapy services provide the confidence to get products to market quickly and safely. -
Process Impurity Testing: Polyethylenimine (PEI) | Process and Product Impurities | Assay Packages | BioReliance® Product Characterization Services | Merck
... used as a transfection reagent to deliver genes into mammalian cells, including Cell and Gene Therapies (CGT). Developers of PEI-employing therapies are required to demonstrate that levels of this impurity have been minimized in their drug substance... -
Drug Abuse Antibodies | Merck
...the influence laws. As a leader in providing diagnostic antibodies and reagents to IVD developers and manufacturers, we have assembled a classic panel of antibodies, paired against the most important Drug of Abuse targets. The antibodies are ... -
Press Release: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius® Bioreactors
Merck today announced that BioInvent International AB, a Swedish company which develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck's Mobius® single-use bioreactors. -
Press Release: Merck Introduces Parteck® SLC, Silica-based Excipient for Enhanced Drug Solubility and Bioavailability
Merck, today introduced Parteck® SLC, a new excipient with a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (API). -
Press Release: Merck's Udit Batra Receives ‘CEO of the Year' Award from CPhI Pharma
Merck today announced that the CEO of its life science business, Udit Batra, was named "CEO of the Year" for 2016 by CPhI Pharma for his commitment to furthering life science innovation globally. -
Process Solutions: Portfolio Announcement | ddPCR Technology
Merck Introduces BioReliance® Droplet Digital PCR Technology for Cell and Gene Therapy Development